The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B2 Impact ASA
F:B28
|
NO |
|
Pieris Pharmaceuticals Inc
F:PI6
|
US |
|
Groupe Guillin SA
PAR:ALGIL
|
FR |
|
O
|
Omnicell Inc
F:OC9
|
US |
|
Windar Photonics PLC
F:7WP
|
DK |
|
Carlo Gavazzi Holding AG
F:D9N0
|
CH |
|
H
|
Helmerich and Payne Inc
F:HPC
|
US |
|
La Francaise de l Energie SA
F:LFX
|
FR |
|
F
|
Fresenius SE & Co KGaA
XHAM:FRE
|
DE |
|
Toyota Motor Corp
F:TOM
|
JP |
|
Fresenius SE & Co KGaA
MIL:FRE
|
DE |
|
F
|
Fideicomiso Irrevocable No 188156
BMV:FCFE18
|
MX |
|
B&M European Value Retail SA
LSE:BME
|
LU |
|
I
|
Integrated Rail and Resources Acquisition Corp
F:5A3
|
US |
|
N
|
Neowiz
KOSDAQ:095660
|
KR |
|
Web Travel Group Ltd
ASX:WEB
|
AU |
|
Meituan
F:9MD
|
CN |
|
Conrad Industries Inc
OTC:CNRD
|
US |
B2 Impact ASA (B28)’s 12-month stock price forecast through November 2027 has a consensus target of €1.863, implying 13% downside. The forecast is based on price targets from 7 Wall Street analysts.
Past growth per year Not enough data
Average annual growth cannot be calculated for these periods.
Explore analyst estimates, growth and forecast ranges.
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
According to Wall Street analysts, the average 1-year price target for B28 is 1.863 EUR with a low forecast of 1.813 EUR and a high forecast of 1.977 EUR.
Over the last 10 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 6%.
Over the last 10 years, the compound annual growth rate for Gross Profit has been 16%. The projected CAGR for the next 3 years is 4%.
Over the last 10 years, the compound annual growth rate for Operating Income has been 19%. The projected CAGR for the next 3 years is 2%.
Over the last 10 years, the compound annual growth rate for Pre-Tax Income has been 13%. The projected CAGR for the next 3 years is 15%.
Over the last 10 years, the compound annual growth rate for Net Income has been 12%. The projected CAGR for the next 3 years is 16%.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Already have an account? Sign in
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more